ImmunityBio, Inc.
IBRX
Peringkat dalam Saham
#2130
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Harga Saham
$9.08
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$9.62B
Perubahan (1 hari)
-9.25%
Perubahan (1 tahun)
278.13%
Negara
US
Perdagangan ImmunityBio, Inc. (IBRX)
Kategori
Healthcare
Margin Operasi untuk ImmunityBio, Inc. (IBRX)
Margin Operasi per October 2026 TTM: -151.88%
Menurut laporan keuangan dan harga saham terbaru dari ImmunityBio, Inc., margin operasi saat ini (TTM) adalah -151.88%. Pada akhir 2023, margin operasi perusahaan adalah -58,239.55%.
Riwayat margin operasi untuk ImmunityBio, Inc. dari 2013 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | -151.88% | -93.49% |
| 2024 | -2,334.23% | -95.99% |
| 2023 | -58,239.55% | -60.21% |
| 2022 | -146,374.17% | 313.93% |
| 2021 | -35,361.88% | -3.14% |
| 2020 | -36,509.09% | 414.51% |
| 2019 | -7,095.87% | -96.61% |
| 2018 | -209,338.30% | -4.96% |
| 2017 | -220,266.67% | -22.15% |
| 2016 | -282,954.55% | 179.55% |
| 2015 | -101,218.64% | 10,344.49% |
| 2014 | -969.11% | 156.26% |
| 2013 | -378.17% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -100.25% |
US
|
|
| -149.01% | -99.02% |
US
|
|
| 25.57% | -100.17% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.19% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.